FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4225746196> ?p ?o ?g. }

• W4225746196 endingPage "e807" @default.
• W4225746196 startingPage "e802" @default.
• W4225746196 abstract "The incidence of lung cancer is increasing yearly worldwide, and targeted medicines are the main choice for lung cancer patients. However, there has been no relevant research about the analysis and adjustment of drug combinations for cancer patients with hypertension and hyperlipidemia until now. Here, we reported a case of medicine adjustment for a patient of lung cancer with hypertension and hyperlipidemia. The patient was diagnosed as right lung adenocarcinoma with lymph node metastasis and continued taking gefitinib tablets to maintain therapeutic efficacy after the end of chemotherapy. Severe paronychia and a high plasma concentration of gefitinib were noticed when the patient visited the hospital for reexamination. The clinical pharmacist found that the patient took nifedipine sustained-release tablets and simvastatin tablets simultaneously, and these medicines were all substrates of CYP3A4. The clinical pharmacist suggested replacing the medicines for hypertension and hyperlipidemia with valsartan capsules (Diovan) and rosuvastatin calcium tablets (Crestor), respectively. The adverse cutaneous reactions were greatly relieved, and the plasma concentration of gefitinib was decreased when another reexamination was performed. Therapeutic drug monitoring was an important method in our case and provided valuable information to develop individualized treatment strategies. For cancer patients suffering from other diseases such as hypertension and hyperlipidemia, it is necessary to pay special attention to the drug-drug interactions and metabolic pathways among drug combinations." @default.
• W4225746196 created "2022-05-05" @default.
• W4225746196 creator A5008957851 @default.
• W4225746196 creator A5020149355 @default.
• W4225746196 creator A5020746135 @default.
• W4225746196 creator A5023368983 @default.
• W4225746196 creator A5028994334 @default.
• W4225746196 creator A5038836690 @default.
• W4225746196 creator A5042281820 @default.
• W4225746196 creator A5075448214 @default.
• W4225746196 creator A5080882253 @default.
• W4225746196 creator A5087245314 @default.
• W4225746196 date "2021-08-27" @default.
• W4225746196 modified "2023-10-16" @default.
• W4225746196 title "Severe adverse cutaneous reactions induced by gefitinib combined with antihypertensive and antihyperlipidemic drugs in lung cancer" @default.
• W4225746196 cites W1592005000 @default.
• W4225746196 cites W1927855523 @default.
• W4225746196 cites W1974470254 @default.
• W4225746196 cites W1997069340 @default.
• W4225746196 cites W2025493301 @default.
• W4225746196 cites W2043384854 @default.
• W4225746196 cites W2125129553 @default.
• W4225746196 cites W2162565810 @default.
• W4225746196 cites W2163147844 @default.
• W4225746196 cites W2193019120 @default.
• W4225746196 cites W2234420107 @default.
• W4225746196 cites W2340963211 @default.
• W4225746196 cites W2345489434 @default.
• W4225746196 cites W2396699631 @default.
• W4225746196 cites W2508069933 @default.
• W4225746196 cites W2600169258 @default.
• W4225746196 cites W2605882066 @default.
• W4225746196 cites W2796638142 @default.
• W4225746196 cites W2808368317 @default.
• W4225746196 cites W2887327838 @default.
• W4225746196 cites W2912693825 @default.
• W4225746196 cites W2919358099 @default.
• W4225746196 cites W3081988620 @default.
• W4225746196 doi "https://doi.org/10.1097/cad.0000000000001226" @default.
• W4225746196 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34459464" @default.
• W4225746196 hasPublicationYear "2021" @default.
• W4225746196 type Work @default.
• W4225746196 citedByCount "2" @default.
• W4225746196 countsByYear W42257461962021 @default.
• W4225746196 crossrefType "journal-article" @default.
• W4225746196 hasAuthorship W4225746196A5008957851 @default.
• W4225746196 hasAuthorship W4225746196A5020149355 @default.
• W4225746196 hasAuthorship W4225746196A5020746135 @default.
• W4225746196 hasAuthorship W4225746196A5023368983 @default.
• W4225746196 hasAuthorship W4225746196A5028994334 @default.
• W4225746196 hasAuthorship W4225746196A5038836690 @default.
• W4225746196 hasAuthorship W4225746196A5042281820 @default.
• W4225746196 hasAuthorship W4225746196A5075448214 @default.
• W4225746196 hasAuthorship W4225746196A5080882253 @default.
• W4225746196 hasAuthorship W4225746196A5087245314 @default.
• W4225746196 hasBestOaLocation W42257461961 @default.
• W4225746196 hasConcept C121608353 @default.
• W4225746196 hasConcept C126322002 @default.
• W4225746196 hasConcept C134018914 @default.
• W4225746196 hasConcept C143998085 @default.
• W4225746196 hasConcept C197934379 @default.
• W4225746196 hasConcept C2776256026 @default.
• W4225746196 hasConcept C2779091943 @default.
• W4225746196 hasConcept C2779438470 @default.
• W4225746196 hasConcept C2780035454 @default.
• W4225746196 hasConcept C2780580887 @default.
• W4225746196 hasConcept C555293320 @default.
• W4225746196 hasConcept C71924100 @default.
• W4225746196 hasConcept C98274493 @default.
• W4225746196 hasConceptScore W4225746196C121608353 @default.
• W4225746196 hasConceptScore W4225746196C126322002 @default.
• W4225746196 hasConceptScore W4225746196C134018914 @default.
• W4225746196 hasConceptScore W4225746196C143998085 @default.
• W4225746196 hasConceptScore W4225746196C197934379 @default.
• W4225746196 hasConceptScore W4225746196C2776256026 @default.
• W4225746196 hasConceptScore W4225746196C2779091943 @default.
• W4225746196 hasConceptScore W4225746196C2779438470 @default.
• W4225746196 hasConceptScore W4225746196C2780035454 @default.
• W4225746196 hasConceptScore W4225746196C2780580887 @default.
• W4225746196 hasConceptScore W4225746196C555293320 @default.
• W4225746196 hasConceptScore W4225746196C71924100 @default.
• W4225746196 hasConceptScore W4225746196C98274493 @default.
• W4225746196 hasIssue "1" @default.
• W4225746196 hasLocation W42257461961 @default.
• W4225746196 hasLocation W42257461962 @default.
• W4225746196 hasLocation W42257461963 @default.
• W4225746196 hasLocation W42257461964 @default.
• W4225746196 hasOpenAccess W4225746196 @default.
• W4225746196 hasPrimaryLocation W42257461961 @default.
• W4225746196 hasRelatedWork W1986383700 @default.
• W4225746196 hasRelatedWork W2044653442 @default.
• W4225746196 hasRelatedWork W2050376166 @default.
• W4225746196 hasRelatedWork W2053686268 @default.
• W4225746196 hasRelatedWork W2186047679 @default.
• W4225746196 hasRelatedWork W2376145427 @default.
• W4225746196 hasRelatedWork W2387455091 @default.
• W4225746196 hasRelatedWork W2390152934 @default.
• W4225746196 hasRelatedWork W2464702708 @default.

• next